SC 13G/A: NewAmsterdam Pharma Co N.V.

AI Summary

SC 13G/A filing by NewAmsterdam Pharma Co N.V..

Risk Assessment

Risk Level: low

Filing Documents

• d856951dsc13ga.htm (SC 13G/A) — 87KB
• d856951dex991.htm (EX-99.1) — 7KB
• 0001193125-24-206196.txt ( ) — 96KB

STATEMENT FILED PURSUANT TO

ITEM 3. STATEMENT FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C) Not applicable.

OWNERSHIP

ITEM 4. OWNERSHIP. (a), (b) and (c)The information contained on the cover pages to this Schedule 13G are incorporated herein by reference. Upon our initial Schedule 13G filing on December 2, 2022, Saga Investments Coöperatief U.A. was the record holder of 4,910,000 NewAmsterdam Ordinary Shares, Amgen Singapore Manufacturing Pte. Ltd. was the sole shareholder of Saga Investments Coöperatief U.A.; Amgen Technology, Limited was the sole shareholder of Amgen Singapore Manufacturing Pte. Ltd.; and Onyx Pharmaceuticals, Inc. and Amgen Inc. were the shareholders of Amgen Technology, Limited (the Amgen Inc. Group). Between July 8, 2024 and August 22, 2024, all of the NewAmsterdam Ordinary Shares held by the Amgen Inc. Group were sold.

OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following

OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON Not applicable.

IDENTIFICATION AND CLASSIFICATION

ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON Not applicable.

IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP Not applicable.

NOTICE OF DISSOLUTION OF GROUP

ITEM 9. NOTICE OF DISSOLUTION OF GROUP Not applicable.

CERTIFICATION

ITEM 10. CERTIFICATION. Not applicable. Page 9 of 10

Signatures

Signatures After reasonable inquiry and to the best of the undersigneds knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Dated: August 23, 2024 SAGA INVESTMENTS COÖPERATIEF U.A. By: /s/ Adam S. Elinoff Name: Adam S. Elinoff Title: Vice President, Finance and Treasurer By: /s/ Jan Bouman Name: Jan Bouman Title: Executive Director AMGEN SINGAPORE MANUFACTURING PTE. LTD. By: /s/ Wallace Torres Name: Wallace Torres Title: Director AMGEN TECHNOLOGY, LIMITED By: /s/ Adam S. Elinoff Name: Adam S. Elinoff Title: Vice President, Finance and Treasurer ONYX PHARMACEUTICALS, INC. By: /s/ Adam S. Elinoff Name: Adam S. Elinoff Title: Vice President, Finance and Treasurer AMGEN INC. By: /s/ Adam S. Elinoff Name: Adam S. Elinoff Title: Vice President, Finance and Treasurer Page 10 of 10 Exhibit Index Exhibit No. Description 99.1 Joint Filing Agreement

View Full Filing

View this SC 13G/A filing on SEC EDGAR